Literature DB >> 1356236

Pharmacokinetic interaction between carbamazepine and neuroleptics after combined prolonged treatment in rats.

W Daniel1, L Janczar, L Danek, W Legrum, K J Netter.   

Abstract

This study investigates how neuroleptics of phenothiazine or thioxanthene structure influence the pharmacokinetics of carbamazepine. Experiments were carried out on male Wistar rats. Carbamazepine and the neuroleptics were administered i.p., separately or together, for 2 weeks in the following daily doses (mg/kg): carbamazepine 15 during the 1st week of treatment and 20 during the 2nd week of treatment, promazine 10, chlorpromazine 2, perazine 10, chlorprothixene 2, flupenthixol 0.5. One hour after the last injection of carbamazepine and/or the neuroleptic, samples of blood plasma and brain were taken to determine the concentrations of carbamazepine and two of its metabolites: 10,11-epoxide and trans-10,11-diol. The neuroleptics increased the concentration of carbamazepine in plasma and in brain, but tended to decrease (with the exception of chlorpromazine) the concentration of the epoxide and increased the concentration of trans-10,11-diol. Metabolic in vitro studies did not show any significant differences between rats treated with carbamazepine alone and those treated with carbamazepine plus neuroleptic in the rates of the carbamazepine epoxidation, of 10,11-epoxide hydrolysis or of 1-naphthol glucuronidation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356236     DOI: 10.1007/bf00168955

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  35 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Metabolic interaction between imipramine and carbamazepine in vivo and in vitro in rats.

Authors:  W Daniel; K J Netter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

3.  Change in haloperidol level due to carbamazepine--a complicating factor in combined medication for schizophrenia.

Authors:  E M Kahn; S C Schulz; J M Perel; J E Alexander
Journal:  J Clin Psychopharmacol       Date:  1990-02       Impact factor: 3.153

4.  A new method for simultaneous purification of cytochrome b5 and NADPH-cytochrome c reductase from rat liver microsomes.

Authors:  T Omura; S Takesue
Journal:  J Biochem       Date:  1970-02       Impact factor: 3.387

5.  Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia.

Authors:  R Kidron; I Averbuch; E Klein; R H Belmaker
Journal:  Biol Psychiatry       Date:  1985-02       Impact factor: 13.382

6.  Inhibitory mechanism of imipramine on barbiturate metabolism in rat liver.

Authors:  K Kakemi; H Sezaki; R Konishi; T Kimura
Journal:  Chem Pharm Bull (Tokyo)       Date:  1971-07       Impact factor: 1.645

Review 7.  Clinical issues in the use of carbamazepine in psychiatry: a review.

Authors:  M Elphick
Journal:  Psychol Med       Date:  1989-08       Impact factor: 7.723

8.  Metabolism of carbamazepine.

Authors:  K Lertratanangkoon; M G Horning
Journal:  Drug Metab Dispos       Date:  1982 Jan-Feb       Impact factor: 3.922

9.  The effect of imipramine and desipramine on mixed function oxidase in rats.

Authors:  W Daniel; J Friebertshäuser; C Steffen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-11       Impact factor: 3.000

10.  Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique.

Authors:  L Bertilsson; B Höjer; G Tybring; J Osterloh; A Rane
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

View more
  2 in total

1.  Studies on interactions between traditional herbal and Western medicines. IV: lack of pharmacokinetic interactions between Saiko-ka-ryukotsu-borei-to and carbamazepine in rats.

Authors:  N Ohnishi; S Nakasako; K Okada; S Umehara; K Takara; K Nagasawa; M Yoshioka; K Kuroda; T Yokoyama
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jan-Jun       Impact factor: 2.441

2.  Reduced Systemic and Brain Exposure with Inhibited Liver Metabolism of Carbamazepine After Its Long-Term Combination Treatment with Piperine for Epilepsy Control in Rats.

Authors:  Tianjing Ren; Min Xiao; Mengbi Yang; Jiajia Zhao; Yufeng Zhang; Mengyun Hu; Yan Cheng; Hong Xu; Chunbo Zhang; Xiaoyu Yan; Zhong Zuo
Journal:  AAPS J       Date:  2019-07-18       Impact factor: 4.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.